#LungCancer #Immunotherapy #ASCO2025 #Oncology

#SCLC #LungCancer #ASCO2025 #CancerEducation

Meu Top 05 #Asco2025 🤮

1 - A da tiarinha (sim, até mais do os 2º colocados)
2 - Genocida-mor (e todas as crias e mulé)
3 - Hugo Marmota
4 - A da Goiabeira
5 - Magno Malte

(mas claro que é quase impossível parar no nº 5)

🤮🤮🤮🤮🤮🤮🤮

Stomach cancer crosses generations and so does the hope for better treatments. This month, we highlight the voices of our Smart Patients community & #ASCO2025 research on gastric cancer care.

Read: I Am…22 to 89: https://ow.ly/lKST50XuVvL

#StomachCancerAwarenessMonth #SmartPatients

Season 11 kicked off with a rebroadcast of updates from #ASCO2025. Dr. Ashley Schreier walks us through key research & what it could mean for people living with MBC.
🎧 Listen (all channels) or 🔗 buff.ly/b2QvK31
#OMBCL #MBC #podcast #BCSM

Season 11 is live!
We’re kicking things off with a rebroadcast of updates from #ASCO2025. Dr. Ashley Schreier walks us through key research & what it could mean for people living with MBC.
🎧 Listen (all channels) or 🔗 buff.ly/b2QvK31
#OMBCL #MBC #podcast #BCSM #CanSky

15/ Based on results of GMMG-CONCEPT presented @ #ASCO2025, which treatment strategy should be used for pts w/ HR NDMM?

💬 reply/comment w/ your answer 💬

1️⃣ Initiate allogeneic SCT
2️⃣ Choose IV instead of subQ
3️⃣ Treat to MRD- then d/c tx
4️⃣ Treat to MRD- & cont maintenance

Missed our recent webinar on the report back from ASCO 2025? Watch the recording anytime to catch up on the latest #MetastaticBreastCancer research from #ASCO2025. Dr. Ashley Schreier breaks down key findings and explains their impact.
Watch here: buff.ly/Qygs1VB
#BCSMn #CanSky

Which emerging therapies for non-muscle-invasive bladder cancer (NMIBC) could shift the treatment landscape? Catch up with key highlights from #ASCO2025 for the latest updates on the future of NMIBC care, on demand with Medthority #MedSky #ASCO #BladderCancer #OncSKy

ow.ly/Wek250WAb0s

Sacituzumab Govitecan and Pembrolizumab: A New First-Line Standard for Advanced TNBC? - Oncology Nurse Advisor “These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

Sacituzumab govitecan plus pembrolizumab improves outcomes when compared to chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1-positive advanced triple-negative #breastcancer. Presented at #ASCO2025, covered by @cancertherapyadv.bsky.social.

bit.ly/3TXI8Y9

#bcsm

📫 Check out the latest issue of our #Cancer and #Aging Research Report!
Read the latest updates from the team and highlights in the geriatric oncology field from the #ASCO2025 Annual Conference.
Don't miss out --> www.mycarg.org?p=52377

IQ Recovery Better With Proton vs Photon Radiotherapy in Kids With NGGCTs - Oncology Nurse Advisor “To our knowledge, this is the first study that demonstrates a clinical advantage of proton therapy for NGGCT,” said David Y. Mak, MD.

Children with CNS NGGCTs may have better #IQrecovery if they receive proton radiotherapy rather than photon radiotherapy. Presented at @ascocancer.bsky.social conference #ASCO2025, covered by @cancertherapyadv.bsky.social.

bit.ly/3TU7Soi

Join us for a special #webinar on highlights from #ASCO2025 focused on #MBC. Dr. Ashley Schreier, breast oncologist at Weill Cornell Medicine, breaks down key research & what it means for those with MBC.
Register here: buff.ly/EnIRLOh
#MBCUpdates #OurMBCLife #BCSM #CanSky

ASCO 2025 Interview: Erika Hamilton As practicing oncologists, we can get bogged down in our individual practices and thus have trouble seeing the bigger picture in...

Recently, I had the chance to reflect on chairing #ASCO2025, the evolving landscape of breast cancer research, and why patient-centered innovation matters more than ever.

#SCRIOncologyPartners

📖 www.emjreviews.com/en-us/amj/on...
#Oncology #BreastCancer #ClinicalTrials #Leadership

Omitting Pelvic Lymphadenectomy Appears Beneficial for Some Cervical Cancer Patients - Oncology Nurse Advisor Undergoing sentinel lymph node biopsy and radical hysterectomy without pelvic lymphadenectomy may reduce the risk of retroperitoneal nodal recurrence and cancer-specific death.

Omitting pelvic lymphadenectomy may be beneficial for patients with early-stage #cervicalcancer undergoing sentinel lymph node biopsy and radical hysterectomy. Presented at the #ASCO2025, covered by @cancertherapyadv.bsky.social.

bit.ly/3IrvMVt

#gyncsm

There was clinical trial at #ASCO2025 that assorted that even cancer protocols based on circadian rhythms were beneficial to patients undergoing tough treatments.
Chronotypes matter. 😁

At #ASCO2025: interim results from the #DESTINY-Breast09 trial, showing that T-DXd plus pertuzumab nearly doubled median PFS compared to THP in first-line HER2-positive metastatic breast cancer, with consistent benefit across all subgroups.
Watch the video: www.docwirenews.com/post/how-des...

Retrouvez notre incontournable TOP5 #ASCO dans chaque spécialité dans le numéro de juin !
👉🏻 onko.fr/asco-2025-de...

#ASCO2025 #oncologiethoracique #sénologie #radiothérapie #oncologiedigestive #oncourologie #orl #oncogynécologie #soinsdesupport

Join us for a special #webinar on highlights from #ASCO2025 focused on #MBC. Dr. Ashley Schreier, breast oncologist at Weill Cornell Medicine, breaks down key research & what it means for those living with MBC.
Register here: buff.ly/EnIRLOh
#MBCUpdates #OurMBCLife #BCSM #CanSky

Shifting First-Line Strategy: Inavolisib Shows OS, PFS Gains in INAVO120 Trial | Docwire News INAVO120 shows OS benefit with inavolisib in PIK3CA-mutated HR+/HER2– aBC, raising new considerations for first-line care.

#INAVO120: Neue Hoffnung für Patientinnen mit #PIK3CA-mutiertem HR+/HER2- Brustkrebs! Auf dem #ASCO2025 stellte Prof. Sibylle Loibl die finale OS-Analyse vor: +7 Monate medianes Überleben mit #Inavolisib + #Palbociclib + #Fulvestrant in der First-Line-Therapie
www.docwirenews.com/post/shiftin...

The @binaytara.bsky.social CME team is heading to El Paso and Boise for back-to-back #BestOfASCO conferences this weekend! Join us for expert-led sessions, key updates from #ASCO2025, and practical insights to improve cancer care.
#CME #Binaytara #HemeOnc #CancerCare

ASCO® 2025 Insights: Sequencing-Guided Chemo Optimization Using ctDNA in Newly Diagnosed DLBCL - The SHORTEN-ctDNA Trial A video from Hua-Jay Cherng (as part of 2025 ASCO® Annual Meeting Insights Hub), posted on Jun 5, 2025.

This #ASCO2025 Insights video highlights @columbiauniversity.bsky.social’s innovative SHORTEN-ctDNA trial using Foresight CLARITY™ MRD to help personalize #chemotherapy treatment and avoid unnecessary toxicity. Watch here: bit.ly/408uxR9
Read the data: bit.ly/43LAvbs

LBCA SAB Chair Dr. Mouabbi and MSKCC ILC program co-lead Dr. Shen, each shared exciting ILC research study results at the American Society of Clinical Oncology conference last month: lobularbreastcancer.org/ilc-research.... #ILC #ASCO2025

📢 ISMO After ASCO 2025 is on tonight!
🕕 6–8PM | 💻 MS Teams
Top Irish & global oncologists sharing ASCO highlights incl. breast, lung, GI, sarcoma & key trials like OASIS-4.

Links sent to all registered.

#ISMO #ASCO2025

Trending at ASCO 2025 : Social Media Insights from X 📊 ASCO 2025 Social Media Insights | Download the Full Report! 📥 👉   How is social media shaping the […] The post Trending at ASCO 2025 : Social Media Insights from X appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Trending at ASCO 2025 : Social Media Insights from X #Insights #ASCO2025 #contentanalytics #HCSM Comment below!

Dr Abramson on ASCO 2025 DLBCL Updates: What's New? Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual Meeting.

Dr. Jeremy Abramson (Mass General/Harvard) spotlighted Foresight CLARITY #MRD detection in a prospective, real-world cohort presented at #ASCO2025.

At Foresight, we’re proud to back tools driving smarter interventions and personalized treatment. Watch here: bit.ly/4kb7o7D

Trending at ASCO 2025 : Social Media Insights from X 📊 ASCO 2025 Social Media Insights | Download the Full Report! 📥 👉   How is social media shaping the […] The post Trending at ASCO 2025 : Social Media Insights from X appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Trending at ASCO 2025 : Social Media Insights from X #Insights #ASCO2025 #contentanalytics #HCSM Comment below!

Trending at ASCO 2025 : Social Media Insights from X 📊 ASCO 2025 Social Media Insights | Download the Full Report! 📥 👉   How is social media shaping the […] The post Trending at ASCO 2025 : Social Media Insights from X appeared first on LucidQuest Ventures.

LucidQuest Views >>> Trending at ASCO 2025 : Social Media Insights from X #Insights #ASCO2025 #contentanalytics #HCSM Comment below!

SOHO Insider - MPN Treatment Advances: Kuykendall & Hobbs Podcast Kuykendall & Hobbs discuss MPN therapies, rusfertide, and ASCO 2025’s VERIFY trial in a SOHO podcast. Explore key insights.

If you haven't listened to our podcast with Drs. Andrew Kuykendall of @moffittnews.bsky.social and Gabby Hobbs of @massgeneralbrigham.bsky.social, you are missing out on a spirited discussion on the latest in MPN, including some #ASCO2025 #ASCO25 news.

sohoinsider.com/soho-insider...

#ASCO25 showcased important clinical trial readouts that promise to reshape cancer treatment across various tumor types. Download our full report for a deeper dive into the latest oncology breakthroughs from our Oncology Center of Excellence. buff.ly/A2LYSOq

#Oncology #CancerResearch #ASCO2025